Expression and Role of Toll-like Receptors in Facial Nerve Regeneration after Facial Nerve Injury.
degeneration
facial nerve
regeneration
toll-like receptor
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
08 Jul 2023
08 Jul 2023
Historique:
received:
07
06
2023
revised:
27
06
2023
accepted:
06
07
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Facial nerve palsy directly impacts the quality of life, with patients with facial nerve palsy showing increased rates of depression and limitations in social activities. Although facial nerve palsy is not life-threatening, it can devastate the emotional and social lives of affected individuals. Hence, improving the prognosis of patients with this condition is of vital importance. The prognosis of patients with facial nerve palsy is determined by the cause of the disease, the degree of damage, and the treatment provided. The facial nerve can be easily damaged by middle ear and temporal bone surgery, trauma or infection, and tumors of the peripheral facial nerve or tumors surrounding the nerve secondary to systemic disease. In addition, idiopathic, acquired immunodeficiency syndrome and autoimmune diseases may damage the facial nerve. The treatment used for facial paralysis depends on the cause. Treatment of facial nerve amputation injury varies depending on the degree of facial nerve damage, comorbidities, and duration of injury. Recently, interest has increased in Toll-like receptors (TLRs) related to innate immune responses, as these receptors are known to be related to nerve regeneration. In addition to innate immune cells, both neurons and glia of the central nervous system (CNS) and peripheral nervous system (PNS) express TLRs. A comprehensive literature review was conducted to assess the expression and role of TLRs in peripheral nerve injury and subsequent regeneration. Studies conducted on rats and mice have demonstrated the expression of TLR1-13. Among these, TLR2-5 and TLR7 have received the most research attention in relation to facial nerve degeneration and regeneration. TLR10, TLR11, and TLR13 increase during compression injury of the facial nerve, whereas during cutting injury, TLR1-5, TLR8, and TLR10-13 increase, indicating that these TLRs are involved in the degeneration and regeneration of the facial nerve following each type of injury. Inadequate TLR expression or absence of TLR responses can hinder regeneration after facial nerve damage. Animal studies suggest that TLRs play an important role in facial nerve degeneration and regeneration.
Identifiants
pubmed: 37511005
pii: ijms241411245
doi: 10.3390/ijms241411245
pmc: PMC10379409
pii:
doi:
Substances chimiques
Toll-Like Receptor 1
0
Toll-Like Receptors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT)
ID : (No. 2022R1F1A107457111) (NRF 2018R1A6A1A03025124) (NRF 2019R1A2C1086807) (NRF 2022R1A2C1091779)
Organisme : Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
ID : (grant number: HV22C0233)
Références
Biomed Res Int. 2019 Jul 18;2019:7420189
pubmed: 31396533
Nat Rev Immunol. 2001 Nov;1(2):135-45
pubmed: 11905821
Trends Neurosci. 2011 May;34(5):269-81
pubmed: 21419501
Int J Mol Sci. 2021 Jul 12;22(14):
pubmed: 34299065
Brain Behav Immun. 2014 Nov;42:232-45
pubmed: 25063708
Glia. 2008 Nov 1;56(14):1532-1540
pubmed: 18803321
Eur J Immunol. 2003 Jul;33(7):1767-75
pubmed: 12811836
Clin Immunol. 2009 Apr;131(1):170-7
pubmed: 19358332
Glia. 2008 Nov 1;56(14):1566-1577
pubmed: 18803324
Curr Top Microbiol Immunol. 2009;336:169-86
pubmed: 19688334
Cell. 1996 Sep 20;86(6):973-83
pubmed: 8808632
Neurosci Lett. 2010 Feb 26;471(1):10-4
pubmed: 20056129
Nature. 1991 May 30;351(6325):355-6
pubmed: 1851964
Annu Rev Cell Dev Biol. 1996;12:393-416
pubmed: 8970732
Sci Immunol. 2021 Jun 25;6(60):
pubmed: 34172587
Laryngoscope. 1996 Dec;106(12 Pt 1):1491-6
pubmed: 8948609
Cell Microbiol. 2003 Mar;5(3):143-53
pubmed: 12614458
Nat Immunol. 2010 May;11(5):373-84
pubmed: 20404851
Laryngoscope. 1999 Aug;109(8):1177-88
pubmed: 10443817
J Neurosci. 2007 Nov 14;27(46):12565-76
pubmed: 18003835
Inflamm Res. 2008 Aug;57(8):379-87
pubmed: 18787777
Acta Neurochir (Wien). 1994;130(1-4):125-39
pubmed: 7725935
J Neurosci. 2016 Jun 8;36(23):6352-64
pubmed: 27277810
Pharmacol Res. 2017 Jan;115:224-232
pubmed: 27894923
JAMA Otolaryngol Head Neck Surg. 2020 Mar 1;146(3):256-263
pubmed: 31971554
Cell. 2006 May 19;125(4):749-60
pubmed: 16713565
Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221090007
pubmed: 35585682
Curr Protein Pept Sci. 2013 Feb;14(1):33-42
pubmed: 23441900
J Clin Med. 2022 Feb 08;11(3):
pubmed: 35160337
J Reconstr Microsurg. 2013 May;29(4):223-32
pubmed: 23303519
Semin Immunol. 1998 Oct;10(5):363-72
pubmed: 9799711
J Biomed Sci. 2013 Aug 28;20:62
pubmed: 23984978
Glia. 2008 Nov 1;56(14):1578-1589
pubmed: 18803325
Nature. 2004 Apr 15;428(6984):764-7
pubmed: 15085136
Curr Opin Otolaryngol Head Neck Surg. 2013 Aug;21(4):346-52
pubmed: 23756337
Science. 1996 Apr 5;272(5258):50-3
pubmed: 8600536
Brain Behav Immun. 2022 May;102:163-178
pubmed: 35176442
Oncotarget. 2017 Aug 10;8(46):80741-80756
pubmed: 29113341
Korean J Pediatr. 2010 Dec;53(12):985-8
pubmed: 21253311
Glia. 2010 Nov 1;58(14):1701-9
pubmed: 20578041